Jennifer Lin Hsiao, MD, FAAD
SESSIONS
F013 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
Mar 8, 2024
•
9:00 AM - 11:00 AM
•
Room 1B
F029 Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach
Mar 8, 2024
•
3:30 PM - 5:30 PM
•
Room 5B
F086 Hidradenitis Suppurativa Management in Kids and Teens
Mar 10, 2024
•
1:00 PM - 3:00 PM
•
Room 30DE
U081 Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage
Mar 11, 2024
•
7:30 AM - 8:30 AM
•
Room 31B
DISCLOSURES
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);